S. Stilgenbauer, B. Coiffier, C. Gisselbrecht, P. Lederlin, R. Forstpointner et al., Appendix:The authors wish to thank the following physicians for collecting samples for MRD analysis

R. 1. Herrmann, A. Hoster, E. Zwingers, and T. , Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma, Journal of Clinical Oncology, vol.27, issue.4, pp.511-518, 2009.
DOI : 10.1200/JCO.2008.16.8435

P. Meusers, M. Engelhard, and H. Bartels, Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis, Hematological Oncology, vol.48, issue.5, pp.365-380, 1989.
DOI : 10.1002/hon.2900070505

K. Fu, D. Weisenburger, and T. Greiner, Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling, Blood, vol.106, issue.13, pp.4315-4321, 2005.
DOI : 10.1182/blood-2005-04-1753

R. Siebert, P. Matthiesen, and S. Harder, Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas, Annals of Oncology, vol.9, issue.5, pp.519-526, 1998.
DOI : 10.1023/A:1008242729509

G. Lenz, M. Dreyling, and E. Hoster, Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG), Journal of Clinical Oncology, vol.23, issue.9, pp.1984-1992, 2005.
DOI : 10.1200/JCO.2005.08.133

J. Romaguera, I. Khouri, and H. Kantarjian, Untreated Aggressive Mantle Cell Lymphoma: Results with Intensive Chemotherapy without Stem Cell Transplant in Elderly Patients, Leukemia & Lymphoma, vol.90, issue.10, pp.77-85, 2000.
DOI : 10.1080/01621459.1958.10501452

J. Romaguera, L. Fayad, and M. Rodriguez, High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine, Journal of Clinical Oncology, vol.23, issue.28, pp.7013-7023, 2005.
DOI : 10.1200/JCO.2005.01.1825

. Van-'t, M. Veer, J. De, and M. Mackenzie, High-dose ara-c and BEAM with autograft rescue in R-CHOP responsive mantle cell lymphoma patients, Br J Haematol, vol.144, issue.4, pp.524-530, 2009.

P. Dreger, N. Von, and R. Kuse, Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma, Annals of Oncology, vol.8, issue.4, pp.401-403, 1997.
DOI : 10.1023/A:1008251301319

P. Dreger, M. Rieger, and B. Seyfarth, Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome, Haematologica, vol.92, issue.1, pp.42-49, 2007.
DOI : 10.3324/haematol.10608

C. Geisler, A. Kolstad, and A. Laurell, Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group, Blood, vol.112, issue.7, pp.2687-2693, 2008.
DOI : 10.1182/blood-2008-03-147025

A. Gianni, M. Magni, and M. Martelli, Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen), Blood, vol.102, issue.2, pp.749-755, 2003.
DOI : 10.1182/blood-2002-08-2476

E. Vandenberghe, C. Ruiz-de-elvira, and F. Loberiza, Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries, British Journal of Haematology, vol.6, issue.5, pp.793-800, 2003.
DOI : 10.1038/sj.bmt.1701400

M. Dreyling, G. Lenz, and E. Hoster, Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network, Blood, vol.105, issue.7, pp.2677-2684, 2005.
DOI : 10.1182/blood-2004-10-3883

R. Delarue, C. Haioun, and V. Ribrag, followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): Final results of a phase II study from the GELA [abstract], Blood, vol.112, issue.11, p.581, 2008.

F. Lefrere, D. A. Levy, and V. , Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study, Haematologica, vol.89, issue.10, pp.1275-1276, 2004.

D. Ritchie, J. Seymour, and A. Grigg, The hyper-CVAD???rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma, Annals of Hematology, vol.53, issue.9, pp.101-105, 2007.
DOI : 10.1007/s00277-006-0193-2

I. Khouri, J. Romaguera, and H. Kantarjian, Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma., Journal of Clinical Oncology, vol.16, issue.12, pp.3803-3809, 1998.
DOI : 10.1200/JCO.1998.16.12.3803

E. Hoster, M. Dreyling, and W. Klapper, A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma, Blood, vol.111, issue.2, pp.558-565, 2008.
DOI : 10.1182/blood-2007-06-095331

M. Ritgen, S. Bottcher, and S. Stilgenbauer, Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial, Leukemia, vol.100, issue.7, pp.1377-1386, 2008.
DOI : 10.1016/j.bbmt.2006.06.004

N. Andersen, J. Donovan, and J. Borus, Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease, Blood, vol.90, issue.10, pp.4212-4221, 1997.

P. Corradini, M. Ladetto, and M. Astolfi, Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma, British Journal of Haematology, vol.94, issue.2, pp.376-378, 1996.
DOI : 10.1046/j.1365-2141.1996.d01-1816.x

P. Corradini, M. Astolfi, and C. Cherasco, Molecular monitoring of minimal residual disease in follicular and mantle cell Non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting, Blood, vol.89, issue.2, pp.724-731, 1997.

M. Ladetto, P. Corradini, and S. Vallet, High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO), Blood, vol.100, issue.5, pp.1559-1565, 2002.
DOI : 10.1182/blood-2002-02-0621

M. Ladetto, D. Marco, F. Benedetti, and F. , Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage, Blood, vol.111, issue.8, pp.4004-4013, 2008.
DOI : 10.1182/blood-2007-10-116749

C. Pott, C. Schrader, and S. Gesk, Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma, Blood, vol.107, issue.6, pp.2271-2278, 2006.
DOI : 10.1182/blood-2005-07-2845

A. Rawstron, B. Kennedy, and P. Evans, Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy, Blood, vol.98, issue.1, pp.29-35, 2001.
DOI : 10.1182/blood.V98.1.29

N. Andersen, J. Donovan, and A. Zuckerman, Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma, Experimental Hematology, vol.30, issue.7, pp.703-710, 2002.
DOI : 10.1016/S0301-472X(02)00807-X

S. Swerdlow, E. Campo, M. Seto, and H. Müller-hermelink, Mature B-cell neoplasms: mantle cell lymphoma eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, pp.229-232

M. Dreyling, E. Hoster, and H. O. , European MCL Network: An update on current first line trials. [abstract], Blood, vol.110, issue.11, p.388, 2007.

S. Bottcher, M. Ritgen, and S. Buske, Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations, Haematologica, vol.93, issue.4, pp.551-559, 2008.
DOI : 10.3324/haematol.11267

C. Pott, M. Tiemann, and B. Linke, Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas, Leukemia, vol.12, issue.10, pp.1630-1637, 1998.
DOI : 10.1038/sj.leu.2401172

J. Van-dongen, A. Langerak, and M. Bruggemann, Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936, Leukemia, vol.17, issue.12, pp.2257-2317, 2003.
DOI : 10.1038/sj.leu.2403202

M. Pongers-willemse, O. Verhagen, and G. Tibbe, Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes, Leukemia, vol.12, issue.12, pp.2006-2014, 1998.
DOI : 10.1038/sj.leu.2401246

V. Van-der-velden, G. Cazzaniga, and A. Schrauder, Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data, Leukemia, vol.17, issue.4, pp.604-611, 2007.
DOI : 10.1038/sj.leu.2404586

B. Cheson, J. Bennett, and K. Kopecky, Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.21, issue.24, pp.4642-4649, 2003.
DOI : 10.1200/JCO.2003.04.036

L. Lin, A Concordance Correlation Coefficient to Evaluate Reproducibility, Biometrics, vol.45, issue.1, pp.255-268, 1989.
DOI : 10.2307/2532051

J. Lundin, E. Kimby, and M. Bjorkholm, Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL), Blood, vol.100, issue.3, pp.768-773, 2002.
DOI : 10.1182/blood-2002-01-0159

O. Howard, J. Gribben, and D. Neuberg, Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival, Journal of Clinical Oncology, vol.20, issue.5, pp.1288-1294, 2002.
DOI : 10.1200/JCO.2002.20.5.1288

N. Andersen, L. Pedersen, and E. Elonen, Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant, European Journal of Haematology, vol.96, issue.2, pp.73-80, 2003.
DOI : 10.1016/S1535-6108(03)00028-X

F. Bosch, A. Ferrer, and N. Villamor, Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication, Clinical Cancer Research, vol.14, issue.1, pp.155-161, 2008.
DOI : 10.1158/1078-0432.CCR-07-1371

P. Moreton, B. Kennedy, and G. Lucas, Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival, Journal of Clinical Oncology, vol.23, issue.13, pp.2971-2979, 2005.
DOI : 10.1200/JCO.2005.04.021

S. Boettcher, K. Fischer, and S. Stilgenbauer, Quantitative MRD assessment predicts progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab ? a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial [abstract], Blood, vol.112, issue.11, p.326, 2008.